Experienced independent investor group, since late 1990, focused on public biotech companies in Nordic markets. We let our performance speak for itself.
Malmö and London
Joined October 2019
- Tweets1K
- Following80
- Followers4K
- Likes121
Pinned Tweet
Disclaimer. Our content is intended for informational purpose only. Our conclusion may be wrong and may cause losses. Do your own research before making any investment.
Coegin Pharma: Phase I/II AK study on track. Danish Medical Agency approve application to start the study. Coegin Pharma follows plan, start in August 2021. coeginpharma.com/media/press…
Synact: follow up conf. 7th July on positive data from the phase 2a trial of AP1189 in Covid-19 infected patients. mb.cision.com/Main/14427/337…
Aegirbio: secured capacity to produce 9 million Covid diagnostic test per month, starting in August. aegirbio.com/news/aegirbio-a…
Please read our disclaimer before you invest. We may be completely wrong and any investment based on our conclusions may cause severe losses.
SynAct Pharma: Patients treated with AP1189 recovered respiratory function on average 3.5 days quicker than did placebo treated patients, a 35% increase in recovery time.
synactpharma.com/en/synact-p…
Chordate Medical:
Clinical evaluation of Chordates K.O.S treatment for rhinitis in public hospitals in Saudi Arabia now approved chordate.com/investor-relati…
The Biotech Analyst Group retweeted
CombiGene and Neurochase begin work to optimize the administration of CG01
combigene.com/en/news-and-re…
Aegirbio: Progress according to plan. Test order worth (revenue) 100 MSEK, with potential to generate (revenue) 200 MSEK per month.
Scandion Oncology: positive interim results from phase II.
Scandion Oncology reports positive interim results from the CORIST Phase II study news.cision.com/scandion-onc…
ExpreS2ion: gap closure today if you are into TA. Bullish engulfing candle in the making? Start phase II, financing sorted and phase I/II data upcoming.
Combigene: Ready to start GMP production CG01 mfn.se/a/combigene/gmp-plasm…
Kancera: According to CEO, results from the Covid-19 study will be presented when the study is completed, hence 90 days after last patient is treated. Presentation of results after 7-days is cancelled due to lack of resources at hospitals and lab. Complete data in Q4 2021
Coegin Pharma: here are some comments on the concept, the upregulated CPLA₂α enzyme in many indications. Technically, in the 1h timeframe an IHS is formed indicating new trading range between 0.7 -1.0 SEK.
Portfolio update: We look forward to follow our new position in Coegin Pharma. Two spinouts and start of phase I/II in August, study completed this year. In our opinion, the two spinouts are not priced in at all in current market cap (likely value when launched 100-200 MSEK).
Coegin Pharma: we think the upcoming two spinouts will be significant triggers in addition to the phase I/II study in actinic keratoses.
